Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01211587 · ClinicalTrials.gov registry record · Phase 2
A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease
A Phase 2 study, sponsored by Newron Pharmaceuticals SPA.
- Completed
- Registry status
- Phase 2
- Development phase
- 103
- Enrollment target
NCT01211587 is a Phase 2 study that has completed, run by Newron Pharmaceuticals SPA. The registered enrollment target is 103 participants.
The verdict
NCT01211587, a Phase 2 study, has completed, sponsored by Newron Pharmaceuticals SPA.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 103 participants
- Enrollment target
Study Summary
The purpose of this research trial is to determine if safinamide (experimental drug) can improve cognition in cognitively impaired but non-demented Parkinson's disease patients. The word "experimental" means the trial drug is not approved by Health Authorities (government authorities) and is still being tested for safety and effectiveness. Approximately one hundred (100) patients will participate in this research trial. The research trial will be conducted in approximately thirty (30) medical centers in the following countries: Argentina, Canada, Italy, Peru, South Africa, Spain and USA. The research trial will last until June 2012.
Interventions
- DRUG placebo
- DRUG safinamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2010-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01211587
The ClinicalTrials.gov registry entry for NCT01211587 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Newron Pharmaceuticals SPA, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01211587 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01211587 about?
NCT01211587 is a clinical study titled "A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease". The purpose of this research trial is to determine if safinamide (experimental drug) can improve cognition in cognitively impaired but non-demented Parkinson's disease patients. The word "experimental" means the trial drug is not approved by Health Authorities (government authorities) and is still b...
What is the current status of trial NCT01211587?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 103 participants. The study started on 2010-09.
What interventions are being tested in trial NCT01211587?
The interventions under investigation include: placebo (DRUG), safinamide (DRUG).
Who is sponsoring clinical trial NCT01211587?
This trial is sponsored by Newron Pharmaceuticals SPA, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.